ROHINGYA FLEE CROWDED CAMPS ON BOATS AS REPATRIATION HOPES FADE
By Eastern Eye Dec 04, 2023
AN INCREASING number of Rohingya people are leaving refugee camps in Bangladesh with their children, taking to boats in search of a better life as hopes fade of returning to Myanmar or being resettled, and camp life gets tougher, aid groups said.
Nearly one million members of the Muslim minority from Myanmar live in bamboo-and-plastic camps in the Bangladeshi border district of Cox’s Bazar, most after fleeing a military crackdown in Myanmar in 2017.
“A few years ago, these boats mostly carried young males,” said Chris Lewa, director of the Arakan Project that helps refugees, referring to small boats that set off from the Bangladesh and Myanmar coasts, usually bound for southeast Asia. “A large number aboard are entire families, parents with children, and sometimes extended families.”
Rohingya traditionally take to sea in October, at the end of the rainy season, on journeys fraught with danger. The boats, often overcrowded, can sink, or run out of food and water, and the Rohingya can fall into the hands of people smugglers.
Out of an estimated 1,084 Rohingya who came ashore in Indonesia’s Aceh province in November, 360 were children, 292 women and 238 men, according to UN refugee agency data.
Of 3,572 Rohingya who left on 34 boats this year, 31 per cent of them were children, data showed.
About 65 per cent of those leaving set off from Bangladesh this year, compared with 27 per cent last year. Most of the rest leave from Myanmar.
In 2022, one of the deadliest years for the Rohingya at sea, a fifth of the about 3,705 people who fled were children.
“Children making the boat journeys was not a trend before,” said Mohammed Mizanur Rahman, Bangladesh’s refugee relief and repatriation commissioner based in Cox’s Bazar.
Rohingya have faced persecution in Buddhist-majority Myanmar for decades. They are generally regarded as foreign interlopers from south Asia, denied citizenship and subjected to abuse.
With little hope of settling in Bangladesh or being accepted elsewhere, they feel they have no choice but to take to the sea, Rahman said. “When an entire section becomes stateless, when they see no prospect of their repatriation or integrating into the countries they are settled in, they obviously become worried about the future of their next generation,” he said.
Aid workers said more families are taking to the sea as conditions in the refugee camps are getting much tougher.
This year, the UN cut food aid to the refugees in Bangladesh by a third, to $8 (£6.30) per person a month because it has been able to raise fewer than half of the $876 million (£690m) needed to support them.
“You can’t even buy an egg with that,” said Rahman, referring to a meal allowance of about 9 Bangladeshi taka (£0.06p) per person.
The chances of going home to Myanmar are more slim than ever. The military government has offered talks on repatriation, but no progress has been made and security is deteriorating with a growing insurgency against military rule.
“No one can think of going back right now,” said refugee Mohammed Taher in Cox’s Bazar, who knows two families that recently set off for Malaysia. “Some people are desperate to leave by any means. They’re ready to take dangerous sea voyages knowing that they can end up dead.”
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.